Scholarlink

<p>Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, metabolic dysregulation, brain insulin resistance, and oxidative stress. Familial AD (fAD) models, like the Tg2576 mice, offer insights into early-onset AD; however, their relevance to sporadic AD remains limited. This study investigated brain insulin signalling and oxidative stress in Tg2576 mice at presymptomatic (7-month) and mild AD (12-month) stages, focusing on the hippocampus and hypothalamus. Additionally, the effects of chronic oral galactose—a proposed insulin-independent energy source—were examined. Oxidative stress parameters remained unchanged across disease progression, aging, and galactose treatment, suggesting that redox processes are not significantly impaired at early stages. Insulin signalling exhibited region- and age-dependent variations, with notable changes in the hypothalamus of 7-month-old transgenic mice. Galactose treatment reduced AMPK activation in both brain regions, potentially reflecting improved energy supply via its conversion to glucose through the Leloir pathway. By 12&#xa0;months of age, hippocampal alterations became more pronounced, including reduced p70S6K activity in transgenic mice, consistent with impaired mTOR signalling in AD. Galactose modulated p70S6K activity differently based on age and genotype: it increased activity in younger wild-type mice, stimulating anabolic processes, while decreasing activity in older wild-type animals. GLUT4 expression also showed nuanced responses to aging, genotype, and galactose treatment. These results highlight the heterogeneity of AD pathophysiology and the limitations of using a single model to represent the disease. The study underscores the need for broad preclinical research to address biological variability and refine therapeutic approaches for both familial and sporadic AD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Insights into insulin signalling and oxidative stress in the Tg2576 mouse model of familial Alzheimer’s disease: effects of chronic oral galactose administration

  • 期刊论文

  • 发表日期：

    2025年6月16日

查看全文
  • Ana Babić Perhoč,
  • Diana Kovač,
  • Jan Homolak,
  • Davor Virag,
  • Ana Knezović,
  • Melita Šalković-Petrišić,
  • Jelena Osmanović Barilar

摘要

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, metabolic dysregulation, brain insulin resistance, and oxidative stress. Familial AD (fAD) models, like the Tg2576 mice, offer insights into early-onset AD; however, their relevance to sporadic AD remains limited. This study investigated brain insulin signalling and oxidative stress in Tg2576 mice at presymptomatic (7-month) and mild AD (12-month) stages, focusing on the hippocampus and hypothalamus. Additionally, the effects of chronic oral galactose—a proposed insulin-independent energy source—were examined. Oxidative stress parameters remained unchanged across disease progression, aging, and galactose treatment, suggesting that redox processes are not significantly impaired at early stages. Insulin signalling exhibited region- and age-dependent variations, with notable changes in the hypothalamus of 7-month-old transgenic mice. Galactose treatment reduced AMPK activation in both brain regions, potentially reflecting improved energy supply via its conversion to glucose through the Leloir pathway. By 12 months of age, hippocampal alterations became more pronounced, including reduced p70S6K activity in transgenic mice, consistent with impaired mTOR signalling in AD. Galactose modulated p70S6K activity differently based on age and genotype: it increased activity in younger wild-type mice, stimulating anabolic processes, while decreasing activity in older wild-type animals. GLUT4 expression also showed nuanced responses to aging, genotype, and galactose treatment. These results highlight the heterogeneity of AD pathophysiology and the limitations of using a single model to represent the disease. The study underscores the need for broad preclinical research to address biological variability and refine therapeutic approaches for both familial and sporadic AD.